On March 27, 2013 the U.S. Food and Drug Administration announced approval of a new drug to treat multiple sclerosis. The drug, Tecfidera (dimethyl fumarate) is approved for use in adult patients relapsing multiple sclerosis (MS). Tecfidera will be launched in 120 mg and 240 mg delayed release capsule formulations. While the exact mechanism of […]
REBIF (interferon beta-1a) – a interferon beta-1a product commonly used to treat relapsing forms of multiple sclerosis. The specific mechanism by which interferon beta-1a exerts its effects in the treatment of multiple sclerosis has not been fully elucidated. FDA approved uses: Rebif is indicated for the treatment of patients with relapsing forms of multiple sclerosis […]
LIDODERM (lidocaine patch 5%) – topical patch formulation of lidocaine commonly used to treat neuropathic pain. Lidocaine is an amide-type local anesthetic agent and is suggested to stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses. The penetration of lidocaine into intact skin after application of LIDODERM is […]
AVONEX (interferon beta 1-a) – an interferon beta product commonly used to treat patients with relapsing forms of multiple sclerosis (MS). The mechanism by which Avonex exerts its effects in the treatment of MS is unknown. FDA approved uses: Avonex is indicated for the treatment of patients with relapsing forms of multiple sclerosis to slow […]